Newer attempts in treating cardiac remodeling and HF have focused on CaMKII and CaN as therapeutic targets [88,89,90,91], however with no clinical success, which is commonly attributed to the lack of specificity and selectivity of the drugs applied [92]. This evidence concerns the gene CAMK2G and hydrops fetalis.